This study aims to test a new drug, JNJ-77242113, for people with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. Researchers will compare it to a placebo (a pill with no medicine) and ustekinumab (an existing psoriasis treatment). To join, you must have plaque psoriasis with or without psoriatic arthritis (joint pain linked to psoriasis), covering at least 10% of your body. You should also need treatments like light therapy or systemic (whole body) treatment. However, if you have a different type of psoriasis or any known allergies to the study drugs, you cannot join. The study excludes those who have had major surgeries recently or have an organ transplant (except for a corneal transplant done over 12 weeks ago).

• The study compares JNJ-77242113 with placebo and ustekinumab.
• Participants must have a specific severity of plaque psoriasis.
• Excludes non-plaque psoriasis and recent major surgery patients.